NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
5/8 — Partial
NUCYNTA ER (tapentadol hydrochloride) by Humanwell Pharmaceutical is centrally-acting synthetic analgesic. First approved in 2011.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUCYNTA ER is an extended-release oral tablet containing tapentadol hydrochloride, a centrally-acting synthetic analgesic approved in 2011. It works via dual mechanism: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It is indicated for moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
$0.053BPart D
LOE Approaching2.8 years to LOEProduct is approaching loss of exclusivity with 2.8 years remaining; commercial teams should anticipate portfolio transition and resource reallocation.
Mechanism of Action
centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
Started Oct 2014
0Moderate to Severe Chronic Non-cancer Pain
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain
Started Oct 2014
0Moderate to Severe Acute Non-Cancer Pain
Why This Matters for Your Career
Worked on NUCYNTA ER at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.